Descripción del proyecto
Tratamiento del trastorno por déficit de atención con hiperactividad y las enfermedades cardiometabólicas
El objetivo del proyecto TIMESPAN, financiado con fondos europeos, es mejorar el tratamiento de enfermos con trastorno por déficit de atención con hiperactividad (TDAH) y enfermedad cardiometabólica concomitante al optimizar las terapias disponibles y la estratificación del riesgo. Las dos afecciones comparten una comorbilidad considerable y una genética común. Además, la enfermedad cardiometabólica provoca muertes prematuras y supone una carga sustancial para los sistemas sanitarios. Es más, no se puede pasar por alto la coexistencia de trastornos psiquiátricos en pacientes con este perfil. Se espera que el trabajo del proyecto mejore los desenlaces clínicos, así como la calidad de vida de los pacientes adultos con TDAH y enfermedad cardiometabólica concomitante.
Objetivo
TIMESPAN's main objective is to advance the management of patients with Attention Deficit Hyperactivity Disorders (ADHD) and co-occurring cardiometabolic disease by improving available treatments and risk stratification. Emerging evidence points at substantial comorbidity and shared genetics between adult ADHD and cardiometabolic diseases (i.e. Obesity, Type-2 Diabetes and cardiovascular disease). Inadequate treatment of cardiometabolic disease is strongly associated with premature death and substantial societal costs. National guidelines of cardiometabolic disease have stressed the importance of co-occurring psychiatric disorders. However, even though ADHD is a common (prevalence ≈2 to 5% in adults) and serious complex chronic condition, knowledge about appropriate management of adults with ADHD and co-occurring cardiometabolic disease is lacking. We will address the main objective using existing large-scale cohort studies and linked electronic health record databases in multiple countries with different health care systems. We also use smartphones and wearable devices to obtain novel real-time and multi-parametric measurements of ADHD medication treatment and cardiometabolic risks. The combined use of unparalleled data sources and new technologies for data collection, management, analytics will identify optimized and personalized multidisciplinary treatment approaches that minimise harm and maximise positive changes in disease prognosis and improve treatment discontinuity. TIMESPAN is expected to improve the clinical outcomes, as well as quality of life in adult ADHD patients with co-occurring cardiometabolic disease and also to also facilitates developments of new technological tools for advanced data management, monitoring and analytics for European stakeholders. TIMESPAN strategies to inform clinicians, patients, health authorities, and general public allow for a sustainable implementation of our findings (e.g. recommendations for treatment guidelines).
Ámbito científico
- medical and health sciencesclinical medicinepsychiatry
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health scienceshealth sciencesnutritionobesity
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2020-Single-Stage-RTD
Régimen de financiación
RIA - Research and Innovation actionCoordinador
70182 Orebro
Suecia